FLASCO OncoFeature – GI Cancer Updates
- September 24, 2024
- OncoFeatures
Press Release by Kellie Jordan, September 24, 2024
Our commitment to advancing oncology care runs deep at the Florida Society of Clinical Oncology (FLASCO). FLASCO provides a united platform to encourage, enhance, and empower collaboration in the oncology discipline. We are dedicated to supporting and empowering our members—whether they are clinicians, researchers, or healthcare professionals—through education, resources, and collaboration.
“FLASCO aims to ensure that every member has access to the latest scientific knowledge and the best tools and support available to improve patient outcomes,” said Julie Newberry, Executive Director of FLASCO. “We recognize the critical importance of continuous learning in our ever-evolving field, and we are honored to provide a range of educational programs that meet the diverse needs of our members. We are proud to introduce the Clinical Oncology Series as FLASCO’s newest educational offerings.”
In early September, FLASCO held its first installment of the Clinical Oncology Series, titled “Multiple Myeloma Updates” spearheaded by a renowned team of Myeloma and Hematology experts. FLASCO will continue the 2024 Clinical Oncology Series in Tampa, Florida on October 12, 2024, featuring “GI Cancer Updates.”
The GI Cancer Updates installment will be a disease-focused summit that will discuss new and emerging therapies, best practices, challenges, and breakthroughs. “Given the limitations of cytotoxic chemotherapy in metastatic colorectal cancer (mCRC), research has increasingly focused on developing targeted therapies based on molecular subtyping,” says Tiago Biachi, MD of Moffitt Cancer Center. “Since the early 2000s, multiple targeted therapies have demonstrated efficacy against KRAS wild-type, BRAF-mutant, and mismatch-repair-deficient disease.”
“More recently, HER2 has emerged as an important therapeutic target in the treatment of HER2-overexpressing (HER2+) mCRC. Several trials, using different eligibility criteria, have shown activity with various agents. Additionally, KRAS, previously regarded only as a marker of resistance to anti-EGFR therapy, is now considered a druggable target in mCRC, with different agents currently under investigation,” Dr. Biachi explains.
FLASCO offers its educational programs free for members and welcomes all clinicians in the GI oncology field to attend. FLASCO is a dues-free state society, and a membership application is available on the FLASCO website https://www.flasco.org “Through collaboration we will stay at the forefront of oncology where innovation meets information,” Newberry added. “Together we leverage the expertise of our membership and our strength in number to be The Voice of Oncology in Florida.”
Register for the FLASCO 2024 Clinical Oncology Series – GI Cancer Updates (and learn about our other educational events) at https://flasco.org/flasco-events/
